Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use

Abstract

Subcutaneous insulin glargine/lixisenatide [Suliqua ® 100/33 and 100/50 (EU); Soliqua ® 100/33 (USA)] is a titratable, fixedratio combination of a long-acting basal insulin analogue + a glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved to treat inadequately controlled type 2 diabetes (T2D) in adults. Once-daily insulin glargine/lixisenatide provided glycaemic control better than that of insulin glargine or lixisenatide in insulin-naive patients (when added to metformin) and better than that of insulin glargine in insulin-experienced patients (when used ± metformin) in phase 3 trials in adults with inadequately controlled T2D. It also had a beneficial effect on bodyweight and did not increase the frequency of hypoglycaemia versus insulin glargine. Insulin glargine/lixisenatide is generally well tolerated and offers the convenience of once-daily administration of two subcutaneous antihyperglycaemic agents. It is, therefore, a valuable option for improving glycaemic control in adults with T2D when this has not been provided by metformin alone or metformin + another oral antihyperglycaemic agent or + basal insulin. Adis evaluation of insulin glargine/lixisenatide in the treatment of T2DOnce-daily fixed-ratio combination of a long-acting insulin analogue (insulin glargine) + a GLP-1 RA (lixisenatide)Titratable to meet the insulin needs of the individual patient Provides better glycaemic control as an add-on to metformin than insulin glargine or lixisenatide in insulinnaive patients Provides better glycaemic control than insulin glargine, when used ± metformin, in insulin-experienced patients Does not increase hypoglycaemic risk vs insulin glargineSafety profile is generally consistent with its components Additional information for this Adis Drug Q&A can be found at https ://doi.org/10.6084/m9.figsh are.96963 38.

Comparisons of efficacy and safety in insulin glargine and lixisenatide plus glulisine combination therapy with multiple daily injection therapy in Japanese patients with type 2 diabetes

“…Interestingly, iGlarLixi (basal insulin glargine U100 [Gla-100] and the short-acting GLP-1 RA lixisenatide [Lixi] at a fixed-dose ratio of 1 U: 1 lg) has been approved for use in Japan. The approved iGlarLixi dose ratio is 3 U:1 lg in the USA, and 3 U:1 lg or 2 U:1 lg in the European Union 14 .…”